Top Markets
Coin of the day
Miravant Medical Technologies Inc. Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT
Classificação em ações #42699
Miravant Medical Technologies Inc. operates as a specialized firm dedicated to... Miravant Medical Technologies Inc. operates as a specialized firm dedicated to pharmaceutical research and development. A cornerstone of its work involves PhotoPoint, an innovative photodynamic therapy designed to eradicate cancerous cells when exposed to light. Furthermore, the company manufactures the essential light-generating and light-delivery devices required for this treatment. Miravant's product pipeline includes several therapeutic agents: PHOTREX, which is aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound developed for managing plaque psoriasis; MV0633, which targets conditions like atherosclerosis, vulnerable atherosclerotic plaque, and restenosis; MV2101, designed to address vascular access graft disease in hemodialysis patients; and MV6401, a treatment under development for solid tumors. The organization, originally established as PDT, Inc., officially adopted its current name, Miravant Medical Technologies Inc., in September of 1997. Founded in 1989, it maintains its corporate headquarters in Santa Barbara, California.
Preço da ação
$0.00001
Última sincronização: 2025-06-16
Valor de mercado
$352.62
Variação (1 dia)
-99.67%
Variação (1 ano)
0.00%
País
US
Negociar Miravant Medical Technologies Inc. (MRVT)

Categoria

Lucros da Miravant Medical Technologies Inc. (MRVT)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Miravant Medical Technologies Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Miravant Medical Technologies Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes